Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00729911 · ClinicalTrials.gov registry record · Phase 4

Ablation vs Amiodarone for Treatment of AFib in Patients With CHF and an ICD

A Phase 4 study of Heart Failure, sponsored by Texas Cardiac Arrhythmia Research Foundation.

Completed
Registry status
Phase 4
Development phase
203
Enrollment target
1
Study location

NCT00729911 is a Phase 4 study of Heart Failure that has completed, run by Texas Cardiac Arrhythmia Research Foundation. The registered enrollment target is 203 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00729911, a Phase 4 study of Heart Failure, has completed, sponsored by Texas Cardiac Arrhythmia Research Foundation.

COMPLETED
Registry status
Phase 4
Development phase
203 participants
Enrollment target
1
Study location

Study Summary

1. To determine if catheter-based atrial fibrillation (AF) ablation is superior to Amiodarone treatment for symptomatic persistent/permanent AF in ICD/CRTD patients with an impaired left ventricular function. 2. Hypothesis: AF ablation is better than Amiodarone for subjects with symptomatic persistent or permanent AF and impaired LV function in terms of recurrence of AF, quality of life, 6-minute walk distance, EF and total number of hospitalizations.

Conditions Studied

Interventions

  • DRUG Amiodarone
  • PROCEDURE Atrial Fibrillation ablation

Study Locations (1)

Texas

  • Texas Cardiac Arrhythmia Research Foundation - Austin

Trial Details

FieldValue
Enrollment Target 203 participants
Start Date 2008-10
Est. Completion 2015-12
Phase Phase 4

What the Registry Record Tells You About NCT00729911

The ClinicalTrials.gov registry entry for NCT00729911 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (90% lower). The listed sponsor is Texas Cardiac Arrhythmia Research Foundation, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Amiodarone is the first listed.

NCT00729911 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00729911 about?

NCT00729911 is a clinical study titled "Ablation vs Amiodarone for Treatment of AFib in Patients With CHF and an ICD". 1. To determine if catheter-based atrial fibrillation (AF) ablation is superior to Amiodarone treatment for symptomatic persistent/permanent AF in ICD/CRTD patients with an impaired left ventricular function. 2. Hypothesis: AF ablation is better than Amiodarone for subjects with symptomatic persiste...

What is the current status of trial NCT00729911?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 203 participants. The study started on 2008-10. Estimated completion is 2015-12.

What conditions does trial NCT00729911 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT00729911?

The interventions under investigation include: Amiodarone (DRUG), Atrial Fibrillation ablation (PROCEDURE).

Who is sponsoring clinical trial NCT00729911?

This trial is sponsored by Texas Cardiac Arrhythmia Research Foundation, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00729911 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.